Close Menu

BGI

The clearances pave the way to clinical applications for three of MGI's instruments but the BGI subsidiary faces legal challenges from Illumina in Europe and the US.

The new complaints add to related patent suits Illumina filed against BGI last year in the US, Germany, Switzerland, and Turkey.

In Nature this week: water lily genome gives glimpse into early evolution of angiosperms, mutations in 140 genes perturb immunophenotype, and more.

The Genome Program, led by technology firm Group 42 in collaboration with BGI and Oxford Nanopore, plans to sequence 100,000 samples during its first phase.

News items for the week of Nov. 11.

With BGI There

Bloomberg Businessweek discusses genomics with BGI's Wang Jian.

MGI Tech will market Pillar Biosciences' Onco/Reveal NGS panels alongside its high-throughput, automated library prep systems outside the US.

Under the non-exclusive agreement, the firms will make Twist's portfolio of NGS target enrichment products available for MGI's sequencing platforms.

MGI hopes to ship the sequencer, one of several products it unveiled at the International Conference on Genomics, to early-access partners in early 2020.

The company claims that certain Illumina sequencers infringe its US Patent No. 9,944,984, "Methods and Compositions for Efficient Base Calling in Sequencing Reactions."

Pages

A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.